Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 3Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma 1Overall Survival 1Melanoma 1Lung Neoplasms 1Inflammatory Breast Neoplasms 1Heart Diseases 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Cardiotoxicity 1

Interventions

Trastuzumab 3Taxes 3Radiotherapy 3Paclitaxel 3Cyclophosphamide 3Epirubicin 2Doxorubicin 2Docetaxel 2Biopsy 2trastuzumab biosimilar HLX02 1talimogene laherparepvec 1romidepsin 1pertuzumab 1pembrolizumab 1pegfilgrastim 1nintedanib 1neratinib 1grapiprant 1eribulin 1caficrestat 1bemcentinib 1Tamoxifen 1Razoxane 1Radiation 1PF-05280014 1Ontruzant 1Ogivri 1Nivolumab 1Neoadjuvant Therapy 1Lapatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Inflammatory Breast Neoplasms × Atorvastatin × Clear all
NCT03872388 2024-10-02

Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

M.D. Anderson Cancer Center

Phase 2 Terminated
6 enrolled 8 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡